Literature DB >> 17895770

Is phosphatemia the best tool to monitor renal tenofovir toxicity?

Marie Essig, Xavier Duval, Firas Al Kaied, Laura Iordache, Anne Gervais, Pascale Longuet, Francoise Blanchet, Gilles Peytavin, Catherine Leport.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17895770     DOI： 10.1097/QAI.0b013e3181142f31

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  7 in total

1.  Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B.

Authors:  Andrés Duarte-Rojo; E Jenny Heathcote
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

Review 2.  Update on tenofovir toxicity in the kidney.

Authors:  Andrew M Hall
Journal:  Pediatr Nephrol       Date:  2012-08-10       Impact factor: 3.714

3.  Short communication: Inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users.

Authors:  Kathryn E Childs; Sarah L Fishman; Catherine Constable; Julio A Gutierrez; Christina M Wyatt; Douglas T Dieterich; Michael P Mullen; Andrea D Branch
Journal:  AIDS Res Hum Retroviruses       Date:  2010-08       Impact factor: 2.205

4.  Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial.

Authors:  Peter L Havens; Charles B Stephensen; Rohan Hazra; Patricia M Flynn; Craig M Wilson; Brandy Rutledge; James Bethel; Cynthia G Pan; Leslie R Woodhouse; Marta D Van Loan; Nancy Liu; Jorge Lujan-Zilbermann; Alyne Baker; Bill G Kapogiannis; Kathleen Mulligan
Journal:  Clin Infect Dis       Date:  2012-01-19       Impact factor: 9.079

5.  Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?

Authors:  Peter L Havens; Jennifer J Kiser; Charles B Stephensen; Rohan Hazra; Patricia M Flynn; Craig M Wilson; Brandy Rutledge; James Bethel; Cynthia G Pan; Leslie R Woodhouse; Marta D Van Loan; Nancy Liu; Jorge Lujan-Zilbermann; Alyne Baker; Bill G Kapogiannis; Catherine M Gordon; Kathleen Mulligan
Journal:  Antimicrob Agents Chemother       Date:  2013-09-03       Impact factor: 5.191

6.  Risk factors associated with hypophosphatemia in chronic Hepatitis B patients treated with tenofovir disoproxil fumarate.

Authors:  Dohyeong Lee; Byung Cheol Yun; Kwang Il Seo; Byung Hoon Han; Sang Uk Lee; Eun Taek Park; Jin Wook Lee; Joonho Jeong
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.817

7.  Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients.

Authors:  Hyung Joon Yim; Ji Hoon Kim; Yong Kyun Cho; Young Oh Kweon; Hyun Chin Cho; Jae Seok Hwang; Changhyeong Lee; Moon Soo Koh; Yang-Hyun Baek; Young-Min Park; Jeong-Hoon Lee; Seung Up Kim; Min-Kyu Kang; Neung Hwa Park; June Sung Lee; Young Eun Chon; Gab Jin Cheon; Hee Bok Chae; Joo Hyun Sohn; Young-Suk Lim
Journal:  Drug Des Devel Ther       Date:  2022-09-23       Impact factor: 4.319
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.